Medical imaging software company MIM Software Inc reported on Wednesday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) for molecular radiotherapy (MRT) dosimetry to target tumors.
The company said MRT is an effective form of therapy that uses radiopharmaceuticals including Lutathera (Lu-177 DOTATATE) and Azedra (I-131 iobenguane) to target tumors based on certain receptors that these tumors express.
In conjunction, MIM SurePlan MRT provides both quantitative SPECT reconstruction and voxel-based absorbed dose calculation by utilizing the patient's own images, allowing for personalized dosimetry measurements. MIM SurePlan MRT provides timesaving tools for organ and tumor segmentation, deformable registration, and voxel-based dosimetry for molecular radiotherapy. The other features include multi-tracer theranostics support, quantitative SPECT and planar corrections and dosimetry reporting tools, added the company.
From 18-19 January 2019, the company will demonstrate MIM SurePlan MRT at the SNMMI 2019 Mid-Winter Meeting in Palm Springs, CA.
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
Merck finalises acquisition of Harpoon Therapeutics Inc
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA
Camurus reports Oclaiz NDA accepted by FDA for acromegaly treatment
TME Pharma plans NOX-A12 Phase 2 trial in brain cancer after FDA IND clearance